GA

Gaurav Agarwal

Active Director Director DIN 08864836
DIN 08864836 First appointment Sep 2020 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2020
Shareholding value •••• Premium profile

About Gaurav Agarwal

Data last updated:

Gaurav Agarwal is a Director at Devann Pharmaceuticals Private Limited (since 2020). The company operates in Healthcare. Devann Pharmaceuticals Private Limited reported revenue of ₹22.7 Lakh (FY 2025).

DIN 08864836
Primary Designation Director
Industry Healthcare
First Appointment 05 Sep 2020
Oldest Company Age 6 yrs
Largest company Devann Pharmaceuticals Private Limited · ₹22.7 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Sep 20202020₹22.7 Lakh (FY 2025)Active

Board colleagues of Gaurav Agarwal

Directorship timeline

Open interactive timeline →
Devann Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Gaurav Agarwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gaurav Agarwal

Gaurav Agarwal currently holds 1 directorship: Devann Pharmaceuticals Private Limited (Director, since 05 Sep 2020, revenue ₹22.7 Lakh (FY 2025)).

Gaurav Agarwal was first appointed on 05 Sep 2020 as Director at Devann Pharmaceuticals Private Limited.

The current boards of Gaurav Agarwal's companies include Shiv Raj Singh (Devann Pharmaceuticals Private Limited), Sumit Sharma (Devann Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available